A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Status:
Recruiting
Trial end date:
2024-03-08
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the
preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary
objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction
of monthly migraine headache days across the 3-month double-blind treatment period.